에 대한 최신 뉴스 Castellum (AMEX:CTM) 주식

Castellum

Castellum Inc is engaged in providing information technology services. The company provides financial services, healthcare, and other users of large data applications with services that include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and MBSE. In addition to constantly innovating and enhancing organic capabilities, Castellum is acquiring technology companies in the areas of cybersecurity, information technology, electronic warfare, information warfare, and information operations with businesses in the defense, federal, civilian, and commercial markets.

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

CWCO

GETY

SAIC

월요일(17일) 아침 미국 지수 선물이 하락세를 보이고 있는 가운데, 오늘 투자자 관심을 끌 수 있는 주식은 다음과 같다. 사이언스 어플리케이션, 게티 이미지, 카스텔럼, 콘솔리테이티드 워터 및 타운스퀘어

월요일 주목해야 할 주식: 사이언스 어플리케이션, 게티 이미지, 카스텔럼, 콘솔리테이티드 워터 및 타운스퀘어

Castellum Inc

CANTERRA MINERALS CORP by Canterra Minerals Corp.

Canterra Minerals Corp

CORPORATE TRAVEL MGMT LTD by Corporate Travel Management Ltd

Corporate Travel Management Ltd

CytomX Therapeutics Inc

Benchmark analyst Mickey Legg reiterates Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) with a Buy and maintains $18 price target.

Price Target

Reiteration

Analyst Ratings

RIVN

Benchmark Reiterates Buy on Rivian Automotive, Maintains $18 Price Target

INDP

Indaptus Therapeutics Shares Resume Trade

Stephens &amp; Co. analyst Mason Carrico reiterates Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Equal-Weight and maintains $17 price target.

STAA

Stephens & Co. Reiterates Equal-Weight on Staar Surgical, Maintains $17 Price Target

ZOOZ Power (Nasdaq and TASE: ZOOZ), a leading provider of flywheel-based power boosters and energy management systems for enabling ultra-fast EV charging solutions, announced today the enhancement of its strategic focus with the introduction of Energy Storage Systems (ESS) and an enhanced Energy Management System (EMS) designed to lead to maximizing EV charging performance and cost efficiency, along with the expansion of its sales team.
The newly introduced Energy Storage System (ESS), in addition to ZOOZ Power's intelligent&#x2A; boosting offering, allows charging operators to significantly reduce electricity costs by storing energy during off-peak periods and deploying it during peak demand hours. This new addition to ZOOZ Power's offering of systems to manage and improve overall power delivery to clusters of ultra-fast EV chargers substantially lowers operational expenses and enhances overall cost efficiency of EV charging infrastructure.
Additionally, ZOOZ Power has upgraded its Energy Management System (EMS), improving the benefits of both the Intelligent Power Booster solution (ZOOSTER) and the new ESS offerings. The advanced EMS operates locally on-site, providing real-time management and rapid response capabilities to efficiently control energy flow, reduce power peaks, and extend battery lifecycles.
The ZOOZTER Intelligent Power Booster continues to play a vital role in ZOOZ Power's comprehensive solution, offering ultra-fast EV charging even in locations with limited grid capacity. By providing high-power bursts during charging sessions, the ZOOZTER effectively mitigates grid constraints, allowing consistent and reliable ultra-fast charging without costly infrastructure upgrades.
In conjunction with its technological advancements, ZOOZ Power is expanding its global sales team. The Company is excited to announce the appointment of Mr. Ilan Tevet as the new Vice President of Global Sales. With over 25 years of experience in global B2B sales, business development and marketing, Ilan has a proven track record of driving growth. His deep expertise will be instrumental in accelerating ZOOZ Power's planned global expansion.
Furthermore, ZOOZ Power is strengthening its worldwide sales presence by appointing new sales managers in strategic markets, including the UK, Germany, and France. Further expansions are planned in other regions to align with the growing adoption of electric vehicles.

ZOOZ

ZOOZ Power Enhances Its Strategic Focus With The Introduction Of Energy Storage Systems And An Enhanced Energy Management System Designed To Lead To Maximizing EV Charging Performance And Cost Efficiency, Along With The Expansion Of Its Sales Team

Stephens &amp; Co. analyst Mason Carrico reiterates Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) with a Overweight and maintains $3.5 price target.

AKYA

Stephens & Co. Reiterates Overweight on Akoya Biosciences, Maintains $3.5 Price Target

A sudden spike in U.S. spot Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44359400/bitcoin-etfs-see-record-5-5-billion-in-outflows-in-5-weeks-as-tariff-turbulence-looms">ETF inflows</a> has caused only a brief rally, with prices reversing in early Tuesday trading.
What Happened: U.S. spot Bitcoin ETFs recorded their highest daily net inflows in six weeks on Monday, totaling $274.6 million. 
This follows five consecutive weeks of net outflows amounting to $5.4 billion, according to SoSoValue <a href="https://sosovalue.xyz/zh/assets/etf">data</a>. 
Analysts attribute the shift to Bitcoin's price stabilization, institutional rebalancing and demand for lower-fee ETFs, The Block <a href="https://www.theblock.co/post/346700/us-spot-bitcoin-etfs-post-largest-daily-net-inflows-in-six-weeks-worth-274-million?utm_source=rss&amp;utm_medium=rss">reported</a>.
Fidelity's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBTC#NASDAQ">FBTC</a>) led inflows with $127.3 million, followed by Ark/21Shares' (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#BATS">ARKB</a>) with $88.5 million and BlackRock's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) with $42.3 million. 
Bitcoin is down 1.7% to $82,000 in Tuesday morning trading.
Analysts anticipate continued fluctuations, with institutional rebalancing potentially driving further inflows or outflows.
As the quarter-end approaches, investors are closely monitoring positioning shifts.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44363871/peter-schiff-slams-bitcoin-etfs-calls-selling-gold-for-btc-worst-timed-trade-in-history">Peter Schiff Slams Bitcoin ETFs, Calls Selling Gold For BTC &#8216;Worst-Timed Trade In History&#8217;</a>
What's Next: Crypto trader Moustache said he is watching this week closely as the FOMC meeting and other key events unfold. 
He predicts a significant price increase, with Bitcoin's consolidation below the daily SMA200 (simple moving average) line indicating bullish momentum.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> I&#39;m really looking forward to this week. Very important events + FOMC and <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> consolidating below the daily SMA200 line (which is actually bullish). I wouldn&#39;t be surprised if we see a big green candle soon. <a href="https://t.co/6EDP3otxX0">pic.twitter.com/6EDP3otxX0</a>
&mdash; 
</blockquote></div></figure>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

IBIT

Bitcoin Meanders Around $82,000 As ETFs Net $275 Million In Inflows

Stephens &amp; Co. analyst Andrew Terrell reiterates Coastal Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCB#NASDAQ">CCB</a>) with a Overweight and maintains $100 price target.

Stephens & Co. Reiterates Overweight on Coastal Finl, Maintains $100 Price Target

D. Boral Capital analyst Jason Kolbert maintains Coya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COYA#NASDAQ">COYA</a>) with a Buy and maintains $18 price target.

COYA

D. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $18 Price Target

Stephens &amp; Co. analyst Mike Scialla upgrades CNX Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNX#NYSE">CNX</a>) from Equal-Weight to Overweight and raises the price target from $35 to $48.

Upgrades

Stephens & Co. Upgrades CNX Resources to Overweight, Raises Price Target to $48

ndaptus Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 56.4%

Wells Fargo analyst Sam Reid maintains Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) with a Equal-Weight and lowers the price target from $130 to $125.

Wells Fargo Maintains Equal-Weight on Lennar, Lowers Price Target to $125

Strategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares are trading lower Tuesday after the company announced an offering of 5 million shares of its Series A Perpetual Strife Preferred Stock in <a href="https://www.benzinga.com/pressreleases/25/03/b44374511/strategy-announces-proposed-strf-perpetual-preferred-stock-offering">a public offering.</a>
Strategy previously said it plans to sell its Perpetual Strife Preferred Stock over an extended period of time. The preferred stock will accumulate cumulative dividends at a fixed rate of 10% per annum.
Strategy has the right to redeem its preferred stock for cash if certain conditions are met. The liquidation preference of the perpetual strife preferred stock is initially set at&nbsp;$100&nbsp;per share. 
Strategy said it intends to use the net proceeds from the offering for general corporate purposes, including the acquisition of additional Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>). The company announced plans in October 2024 to raise <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41818982/will-microstrategys-42-billion-bitcoin-bet-boost-mstr-stock-further">$42 billion</a> over the next three years in an effort to keep stacking Bitcoin.
As of March 9, Strategy held an aggregate of approximately 499,096 Bitcoin, acquired at an average purchase price of approximately $66,357 per coin.
MSTR Price Action: <a href="http://benzinga.com/quote/mstr">Strategy shares</a> were down 4.17% at $282.00 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44374550/bernstein-targets-310-for-coinbase-stock-cites-lifting-regulatory-dark-cloud">Bernstein Targets $310 For Coinbase Stock, Cites Lifting &#8216;Regulatory Dark Cloud&#8217;</a></li>
</ul>
Photo: Shutterstock.

Movers

MSTR

Strategy Stock Is Sliding Tuesday: What's Going On?

Stephens &amp; Co. analyst Mike Scialla upgrades EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) from Equal-Weight to Overweight and raises the price target from $41 to $59.

Stephens & Co. Upgrades EQT to Overweight, Raises Price Target to $59

<ul>
<li>First US Phase 3 study of Photodynamic Therapy (PDT) to include neck, trunk and extremities</li>
<li>Protocol involves one or two PDT treatments using 1-3 tubes of Ameluz&#xAE; or vehicle gel over a surface area of up to 240 cm2
<ul>
<li>Treatment phase expected to be complete by Q3 2025</li>
</ul>
</li>
</ul>

Biotech

General

BFRI

Biofrontera Completes Patient Enrollment Of Phase 3 Study Of Ameluz Topical Gel, 10% For Actinic Keratoses On Extremities\

Wells Fargo analyst Larry Biegelsen maintains Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) with a Equal-Weight and raises the price target from $1.1 to $1.29.

HYPR

Wells Fargo Maintains Equal-Weight on Hyperfine, Raises Price Target to $1.29

On Tuesday, Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock is sliding. The company shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.
The company reported a patient death following treatment with Elevidys, having suffered acute liver failure.
Acute liver injury is a known possible side effect of Elevidys and other AAV-mediated gene therapies and is highlighted in the prescribing information.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42883730/solid-biosciences-outpaces-competitors-in-duchenne-gene-therapy-development" rel="noreferrer noopener">Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development</a>
The company <a target="_blank" href="https://investorrelations.sarepta.com/static-files/0d505d91-6722-4528-aae0-1e99fcbc37e5" rel="noreferrer noopener">says</a> although it is not a new safety signal and the benefit-risk of Elevidys remains positive, acute liver failure leading to death represents a severity of acute liver injury not previously reported for Elevidys, which to date has been used to treat more than 800 patients in clinical trials or as a prescribed therapy.
In addition, testing revealed that this patient had a recent cytomegalovirus (CMV) infection, which the treating physician identified as a possible contributing factor. CMV can infect and damage the liver, a condition known as CMV hepatitis.
Elevidys is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of Elevidys micro-dystrophin in skeletal muscle.
In January, Sarepta Therapeutics&nbsp;released topline results from Part 2 of the EMBARK <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43232532/sarepta-therapeutics-duchenne-gene-therapy-shows-sustained-benefits-and-disease-stabilization-at-two-years" rel="noreferrer noopener">Phase 3 study of Elevidys</a>.
Despite being one year older (average age 7.18 years) than those treated in Part 1 (average age 5.98 years), crossover-treated patients showed clinically meaningful and statistically significant functional benefit for NSAA, Time to Rise (TTR) and 10-meter walk/run (10MWR) function tests compared with a pre-specified, propensity-weighted external control group.
In June 2024, the FDA approved the labeled indication for&nbsp;Elevidys to include individuals with Duchenne muscular dystrophy who have a confirmed mutation in the&nbsp;DMD gene and are at&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39437296/sareptas-expanded-fda-approval-for-elevidys-potentially-shaping-future-fda-reviews-" rel="noreferrer noopener">least&nbsp;four years old</a>.
Price Action: SRPT stock is down 22.90% at $78.10 during the premarket session at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44375605/tencent-musics-q4-revenue-beats-street-view-but-monthly-active-users-fall-over-3" target="_blank" rel="noreferrer noopener">Tencent Music&#8217;s Q4 Revenue Beats Street View, But Monthly Active Users Fall Over 3%</a></li>
</ul>

Health Care

SRPT

Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges

Stephens &amp; Co. analyst Mike Scialla upgrades Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) from Equal-Weight to Overweight and raises the price target from $86 to $123.

Stephens & Co. Upgrades Expand Energy to Overweight, Raises Price Target to $123

BigBear.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) shares are trading lower Tuesday after the company said it identified the need to <a href="https://www.benzinga.com/pressreleases/25/03/b44179893/bigbear-ai-announces-fourth-quarter-and-full-year-2024-results-and-provides-2025-outlook">restate certain prior financial statements</a>.
What Happened: In a new regulatory filing Tuesday morning, BigBear.ai disclosed the need to restate its financial results for the fiscal years ended December&nbsp;31, 2022 and 2023 and the interim financial statements for each quarterly period in 2023 and in 2024. 
The company said prior financial statements should no longer be relied upon after reviewing the accounting for the embedded conversion option of its convertible notes due in 2026. 
BigBear.ai said it will need additional time to determine the impact on the company&#8217;s historical financial statements. As a result, the company requires more time to file its annual report for the fiscal year ended December&nbsp;31, 2024. 
Don&#8217;t Miss: <a href="https://www.benzinga.com/news/earnings/25/03/44180568/bigbear-ai-stock-plummets-after-q4-eps-revenues-miss-details">BigBear.ai Stock Plummets After Q4 EPS, Revenues Miss: Details</a>
BigBear.ai said it estimates that it will need to restate 2023 income before taxes to negative $71.3 million, down from negative $60.3 million. The company expects to change 2024 income before taxes to negative $296.1 million, down from negative $257.1 million.
BigBear.ai noted that it doesn&#8217;t expect any changes to impact its revenue, gross margin, adjusted EBITDA or operating cash flows in any prior period. The company anticipates full-year 2024 revenue of approximately $158.2 million, up from $155.2 million year-over-year. BigBear.ai also expects to report 2024 gross margin of approximately $45.2 million, up from $40.6 million in 2023.
As of December&nbsp;31, 2024, the outstanding principal balance of the company&#8217;s 2026 Notes was&nbsp;$17.7&nbsp;million.&nbsp;
BBAI Price Action: <a href="http://benzinga.com/quote/bbai">BigBear.ai shares</a> were down 12% at $3.07 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
This illustration was generated using artificial intelligence via Midjourney.

BBAI

BigBear.ai Stock Is Trading Lower Today: What's Happening?

5-year agreement targeting 200 vehicle conversions in first year and 1,600 over five years
Provides local sales, service, and maintenance, further boosting Tembo's position in the East African market, a population exceeding 500 million people
AVA's vehicle assembly facilities have the capacity to assemble 30,000 vehicles per annum
AVA currently assembles vehicles for leading OEMs including Toyota, Fuso, Proto, Hino, Mahindra, Scania, Tata, Volvo and Daewoo
Established in 1975, AVA is the only assembler in the region to have achieved IATF16949 Certification
LONDON, March 18, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>) ("VivoPower" or the "Company") announced today that its subsidiary, Tembo e-LV ("Tembo"), has signed a Definitive Heads of Agreement ("Agreement") with Associated Vehicle Assemblers Ltd. ("AVA"), East Africa's market leading vehicle assembler.
The Agreement covers Kenya, Tanzania and other East African nations. With a population exceeding 500 million people, East Africa is the largest sub-region in Africa and home to the United Nations headquarters for Africa.
Under the terms of the Agreement, AVA is empowered to both distribute and locally assemble Tembo's 100% electric utility vehicle (EUV) solutions across East Africa for customers in the mining, agriculture, energy, safari, non-government organisation (NGO), defence and government sectors. Crucially, it provides customers and partners in the East African region with local maintenance and support capabilities. This Agreement augments a previous partnership agreement that Tembo signed with ETC Group in relation to Kenya specifically.
The Agreement reflects both companies' commitment to supporting Kenya's transition to sustainable transportation and creating value and jobs in local economies across East Africa.

Global

VVPR

VivoPower's Tembo Signs 5-Year Agreement With AVA Targeting 1.6K Electric Vehicle Conversions, Expands East African Presence, Utilizes AVA's 30K Annual Vehicle Assembly Capacity, Enhances Local Maintenance in Region

Keybanc analyst Justin Patterson maintains Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) with a Overweight and lowers the price target from $95 to $85.

Keybanc Maintains Overweight on Zillow Gr, Lowers Price Target to $85

Press Releases

Castellum Announces Pricing of $3.7 Million Public Offering of Common Stock

Castellum, Inc.'s SBA Protégés Successfully Onboard to SeaPort-NxG Contract

Contracts

Castellum Announces the Award of a $3.2 million Contract to its Specialty Systems, Inc. Subsidiary

Castellum, Inc. Announces Its GTMR Subsidiary Has Been Selected as a SCI MAC Vendor

Castellum, Inc. Announces 2024 Unaudited Financial Results

Castellum, Inc. Announces the Award of a $103.3 million Contract to its GTMR Subsidiary

Management

Castellum, Inc. Hires Tanya Bassett as Vice President of Business Development and Capture Management; Reinforces Strategic Commitment to Organic Growth

Castellum Announces Proposed Public Offering of Common Stock and Warrants

Castellum Announces Pricing of $4.5 Million Public Offering of Common Stock and Warrants

Castellum, Inc.'s Subsidiary GTMR Achieves CMMI Level 3 Appraisal

Accenture plc Class A Ordinary Shares (Ireland)

Accenture

ASGN

Alpha Technology Group Limited - Class A Ordinary Shares

Alpha Technology Group

BigBear.ai Hldgs

CI&T

Cognizant Technology Solutions Corporation - Class A Common Stock

Cognizant Tech Solns

Endava plc American Depositary Shares (each representing one Class A Ordinary Share)

Endava

DXC Technology

EPAM Systems

Grid Dynamics Holdings, Inc. - Class A Common Stock

Grid Dynamics Holdings

Globant

Hackett Group

International Business Machines Corporation Common Stock

Information Services Group, Inc. - Common Stock

Information Servs Gr

Infosys Limited American Depositary Shares

Infosys

Gartner

Kyndryl Hldgs

MicroAlgo

Research Solutions

Trident Digital Tech Holdings Ltd - American Depository Shares

Trident Digital Tech

Unisys

Wipro

Youxin Technology Ltd - Class A Ordinary shares

Youxin Technology

EF Hutton

월요일(17일) 아침 미국 지수 선물이 하락세를 보이고 있는 가운데, 오늘 투자자 관심을 끌 수 있는 주식은 다음과 같다.
<ul>
<li>사이언스 어플리케이션스 인터내셔널 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>): 월요일 개장 전 실적을 발표할 예정이며, 분기 실적을 주당 2.08달러, 매출 18억 1,000만 달러로 예상하고 있다. <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noopener">Benzinga Pro </a>데이터에 따르면 지난 금요일 주가는 0.2% 상승하여 104.43달러로 마감했다.</li>
<li>게티 이미지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>): 월요일 장 마감 후 실적을 발표할 예정이며, 분기 실적을 주당 4센트, 매출 2억 4,631만 달러로 예상하고 있다. 지난 금요일 주가는 2% 상승하여 2.04달러로 마감했다.</li>
<li>카스텔럼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTM#NYSE">CTM</a>)은 보통주와 워런트의 공모를 제안했다. 금요일 애프터마켓에서 22.03% 하락하여 0.92달러에 거래되었다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noopener">프리마켓 보도</a>를 확인하세요.
<ul>
<li>콘솔리데이티드 워터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWCO#NASDAQ">CWCO</a>): 분기 실적을 주당 28센트, 매출 3,360만 달러로 예상하고 있다. 금요일에 주식은 2.8% 상승하여 29.18달러로 마감했다.</li>
<li>다운스퀘어 미디어 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSQ#NYSE">TSQ</a>): 월요일 개장 전 실적을 발표할 예정이며, 분기 실적은 주당 60센트, 매출 1억 1,641만 달러로 예상한다. 주가는 지난 금요일 애프터마켓에서 1.9% 상승하여 7.94달러에 거래되었다.</li>
</ul>
사진 제공: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Castellum

뉴스

에 대한 최신 뉴스 Castellum (AMEX:CTM) 주식

월요일, 3월 17, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌